admin, Author at EMBARC

EMBARC – Awards and Events

The first EMBARC annual meeting was held at the ERS annual congress in Munich, Germany September 8th 2014. The meeting was well attended, with members from EMBARC, ERS, industry, patient organisations and the United States Bronchiectasis Registry in attendance. The …

EMBARC – A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis

Journal Ref: Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4. Abstract: This randomised double-blind placebo-controlled parallel-group multicentre phase IIa study evaluated the effect of the CXCR2 antagonist AZD5069 on sputum neutrophil counts in adults with bronchiectasis.Patients were …

EMBARC – A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonisation on Prognosis in Adult Bronchiectasis.

Journal Ref: Ann Am Thorac Soc. 2015 Sep 10. [Epub ahead of print] Abstract: Eradication and suppression of Pseudomonas aeruginosa is a key priority in national guidelines for bronchiectasis, and is a major focus of drug development and clinical trials. …

EMBARC – The reproducibility and responsiveness of the lung clearance index in bronchiectasis.

Journal Ref: Eur Respir J. 2015 Sep 4. pii: ERJ-00152-2015. doi: 10.1183/13993003.00152-2015. [Epub ahead of print] Abstract: Lung clearance index (LCI) is a potential clinical outcome marker in bronchiectasis. Its responsiveness to therapeutic intervention has not been determined. This study …

EMBARC – Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity

Journal Ref: Ann Am Thorac Soc. 2015 Oct 2. [Epub ahead of print] Abstract: Testing for underlying etiology is a key part of bronchiectasis management, but it is unclear whether the same extent of testing is required across the spectrum …

EMBARC – Interventions for enhancing adherence to treatment in adults with bronchiectasis.

Journal Ref: Cochrane Database Syst Rev. 2015 Nov 18;11:CD011023. doi: 10.1002/14651858.CD011023.pub2. Review Abstract: Bronchiectasis is characterised by a widening of the airways, leading to excess mucus production and recurrent infection. It is more prevalent in women and those in middle …

EMBARC – Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial.

To compare the efficacy of three slow expiratory airway clearance techniques (ACTs). DESIGN: Randomised crossover trial. SETTING: Tertiary hospital. PARTICIPANTS: Thirty-one outpatients with bronchiectasis and chronic sputum expectoration. INTERVENTIONS: Autogenic drainage (AD), slow expiration with glottis opened in lateral posture …

EMBARC – Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients.

It is general belief that Non-cystic fibrosis bronchiectasis (NCFB) is characterized by frequent community-acquired pneumonia. Nonetheless, the knowledge on clinical characteristics of CAP in NCFBE is poor and no specific recommendations are available. We aim to investigate clinical and microbiological …

EMBARC – State of the art review: management of bronchiectasis in adults.

Journal Ref: Eur Respir J. 2015 Mar 18. pii: ERJ-01191-2014. [Epub ahead of print] Abstract: Formerly regarded as a rare disease, bronchiectasis is now increasingly recognised and a renewed interest in the condition is stimulating drug development and clinical research. …

EMBARC – Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T Cell Immunity to OprF.

Journal Ref: Am J Respir Crit Care Med. 2015 Mar 19. [Epub ahead of print] Abstract: Pseudomonas aeruginosa (PA) is an environmental pathogen that commonly infects individuals with cystic fibrosis (CF) and non-CF bronchiectasis, impacting on morbidity and mortality. To …